人乳头瘤病毒疫苗
本文综述了HPV疫苗的研发基础、上市历程与全球应用现状。现有预防性疫苗基于L1主要衣壳蛋白自组装形成的病毒样颗粒,均靶向HPV-16和HPV-18。截至2020年,已有超过100个国家将HPV疫苗纳入国家免疫规划,上市后数据证实了其有效性和安全性。
要点
- 现有预防性HPV疫苗均靶向HPV-16和HPV-18,这两种型别导致大多数HPV相关癌症。
- 截至2020年,HPV疫苗已纳入超过100个国家的国家免疫规划。
- 多数项目针对年轻青少年女孩接种,越来越多项目也将男孩纳入。
核心结论
- HPV疫苗是最有效的疫苗之一,是首个无需特异性诱导黏膜免疫即可预防嗜黏膜性传播病原体感染的疫苗。
- 上市前试验中的有效性和安全性已被国家免疫规划数据证实。
- 观察到的显著影响和效果激发了对雄心勃勃的疾病削减目标的兴趣。
研究设计与样本
- 综述类文章,检索范围未在原文中报告。
主要发现
- 现有预防性HPV疫苗基于L1主要衣壳蛋白自组装形成的病毒样颗粒。
- 首个HPV疫苗于2006年获批上市。
- 所有疫苗均靶向HPV-16和HPV-18,这两种型别导致大多数HPV相关癌症。
- 截至2020年,HPV疫苗已引入超过100个国家的国家免疫规划。
- 疫苗接种政策已演变,多数项目针对年轻青少年女孩,越来越多项目也纳入男孩。
临床怎么用
- 临床可参照国家免疫规划政策,对年轻青少年女孩接种HPV疫苗,并关注男孩接种的扩展趋势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human papillomavirus (HPV) vaccines are among the most effective vaccines available, the first to prevent infection by a mucosatropic sexually transmitted infectious agent and to do so without specific induction of mucosal immunity. Currently available prophylactic HPV vaccines are based on virus-like particles that self-assemble spontaneously from the L1 major capsid protein. The first HPV vaccine was licensed in 2006. All vaccines target HPV-16 and HPV-18, types which cause the majority of HPV-attributable cancers. As of 2020, HPV vaccines had been introduced into national immunization programs in more than 100 countries. Vaccination polices have evolved; most programs target vaccination of young adolescent girls, with an increasing number also including boys. The efficacy and safety found in prelicensure trials have been confirmed by data from national immunization programs. The dramatic impact and effectiveness observed has stimulated interest in ambitious disease reduction goals.
引用
- Markowitz LE, Schiller JT. Human Papillomavirus Vaccines. J Infect Dis. 2021. PMID: 34590141. doi:10.1093/infdis/jiaa621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。